All Stories

  1. Family-Oriented and Individual-Oriented Lived Experiences in the Narrative Descriptions of Sibling Dyads with Parents Diagnosed with Bipolar Disorder
  2. Using Wearable Device and Machine Learning to Predict Mood Symptoms in Bipolar Disorder: Development and Usability Study
  3. Using Wearable Device and Artificial Intelligence to Predict Mood Symptoms in Bipolar Disorder (Preprint)
  4. Dose-tapering trajectories in patients with remitted psychosis undergoing guided antipsychotic reduction to reach minimum effective dose
  5. The plasma level of complement component 4A decreases with aripiprazole treatment in patients with early psychosis
  6. The changes of parental functioning of the patients with bipolar disorder and major depression since discharging from hospital: A longitudinal study
  7. Follow-up of subjects labelled with putative pre-psychotic states: Viewed from a transdiagnostic clinical high-at-risk mental state (CHARMS) paradigm
  8. Niacin skin flush and membrane polyunsaturated fatty acids in schizophrenia from the acute state to partial remission: a dynamic relationship
  9. Characterization of clinical features and comorbidities between bipolar affective disorder with and without depressive episodes
  10. Dysregulated affective arousal regulates reward-based decision making in patients with schizophrenia: an integrated study
  11. Discontinuing Antipsychotic Medication After Remission from First-Episode Psychosis: A Survey of Psychiatrists’ Attitudes in Taiwan
  12. Detection of advanced brain aging in schizophrenia and its structural underpinning by using normative brain age metrics
  13. Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
  14. A quarter of century after: The changing ecology of psychiatric emergency services
  15. Challenging the Minimum Effective Antipsychotic Dose During Maintenance: Implications From 10-Year Follow-Up of First Episode Psychosis
  16. The experiences of family resilience from the view of the adult children of parents with bipolar disorder in Chinese society
  17. Protocol of guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis based on pragmatic design
  18. Mismatch negativity and P3a in drug-naive adults with attention-deficit hyperactivity disorder
  19. Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms?
  20. P50, N100, and P200 Auditory Sensory Gating Deficits in Schizophrenia Patients
  21. Clinical implications of oxidative stress in schizophrenia: Acute relapse and chronic stable phase
  22. Mismatch negativity to different deviant changes in autism spectrum disorders: A meta-analysis
  23. Social cognition in schizophrenia: A network-based approach to a Taiwanese version of the Reading the Mind in the Eyes test
  24. P50-N100-P200 sensory gating deficits in adolescents and young adults with autism spectrum disorders
  25. Stigmas toward psychosis‐related clinical features among the general public in Taiwan
  26. Clinical characteristics and outcomes associated with weekend admissions to psychiatric wards in Taiwan
  27. Points that need attention in quantitative EEG gamma synchronization
  28. Transcriptome Changes in Relation to Manic Episode
  29. Auditory Event-Related Potentials in Antipsychotic-Free Subjects With Ultra-High-Risk State and First-Episode Psychosis
  30. Genetic associations and expression of extra-short isoforms of disrupted-in-schizophrenia 1 in a neurocognitive subgroup of schizophrenia
  31. Sex as a Moderating Factor in the Relationship Between Hippocampal Volume and Sensory Gating in Patients With Schizophrenia
  32. Advanced Paternal Age and Early Onset of Schizophrenia in Sporadic Cases: Not Confounded by Parental Polygenic Risk for Schizophrenia
  33. Points that need attention in auditory N100 gating research in schizophrenia
  34. Association between mismatch negativity and voxel-based brain volume in schizophrenia
  35. Trajectories after first-episode psychosis: Complement to ambiguous outcomes of long-term antipsychotic treatment by exploring a few hidden cases
  36. T182. SHARED AND DISTINCT ALTERATIONS IN THE WHITE MATTER TRACTS OF REMITTED AND NON-REMITTED PATIENTS WITH SCHIZOPHRENIA
  37. Comparative effect of antipsychotics on risk of self‐harm among patients with schizophrenia
  38. Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia
  39. Mismatch Negativity and P3a in Adolescents and Young Adults with Autism Spectrum Disorders: Behavioral Correlates and Clinical Implications
  40. Impacts of Electroconvulsive Therapy on 1-Year Outcomes in Patients With Schizophrenia: A Controlled, Population-Based Mirror-Image Study
  41. Polygenic risk for schizophrenia and neurocognitive performance in patients with schizophrenia
  42. Bipolar patients treated with long-acting injectable risperidone in Taiwan: A 1-year mirror-image study using a national claims database
  43. Misfortune may be a blessing in disguise: Fairness perception and emotion modulate decision making
  44. Metformin-induced acute dystonia in a schizophrenic patient treated with sulpiride and clozapine
  45. Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder
  46. Haplotypes of the D-Amino Acid Oxidase Gene Are Significantly Associated with Schizophrenia and Its Neurocognitive Deficits
  47. Aberrant expression of microRNAs as biomarker for schizophrenia: from acute state to partial remission, and from peripheral blood to cortical tissue
  48. Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics
  49. Primary and secondary alterations of white matter connectivity in schizophrenia: A study on first-episode and chronic patients using whole-brain tractography-based analysis
  50. Automatic whole brain tract-based analysis using predefined tracts in a diffusion spectrum imaging template and an accurate registration strategy
  51. Initiating long-acting injectable antipsychotics during acute admission for patients with schizophrenia – A 3-year follow-up
  52. Effects of affective arousal on choice behavior, reward prediction errors, and feedback-related negativities in human reward-based decision making
  53. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial
  54. Neurocognitive functioning of subjects with putative pre-psychotic states and early psychosis
  55. Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms
  56. Altered integrity of the right arcuate fasciculus as a trait marker of schizophrenia: A sibling study using tractography-based analysis of the whole brain
  57. A recently-discovered NMDA receptor gene, GRIN3B, is associated with duration mismatch negativity
  58. The tridimensional personality of male heroin users treated with methadone in Taiwan
  59. Identification of novel loci for bipolar I disorder in a multi-stage genome-wide association study
  60. Stable signatures of schizophrenia in the cortical–subcortical–cerebellar network using fMRI of verbal working memory
  61. Olanzapine-Induced Hyponatremia in a Patient with Autism
  62. Facial and Prosodic Emotion Recognition Deficits Associate with Specific Clusters of Psychotic Symptoms in Schizophrenia
  63. Frequency Dependent Alterations in Regional Homogeneity of Baseline Brain Activity in Schizophrenia
  64. A Diagnostic Model Incorporating P50 Sensory Gating and Neuropsychological Tests for Schizophrenia
  65. Aripiprazole for Drug-Naive or Antipsychotic-Short-Exposure Subjects With Ultra-High Risk State and First-Episode Psychosis
  66. Screen for Putative Pre-psychotic States
  67. Development of a brief self-report questionnaire for screening putative pre-psychotic states
  68. Medical costs and vasculometabolic comorbidities among patients with bipolar disorder in Taiwan — A population-based and matched-control study
  69. Frequency-specific alternations in the amplitude of low-frequency fluctuations in schizophrenia
  70. Auditory event-related potential of subjects with suspected pre-psychotic state and first‐episode psychosis
  71. Zotepine-related myopathy in a patient with schizophrenia
  72. Comorbid prevalence of alcohol dependence, substance abuse, and external cause of injury in patients with bipolar disorder in a nationwide representative sample in Taiwan
  73. Neutropenia Associated With the Comedication of Quetiapine and Valproate in 2 Elderly Patients
  74. Medium-term course and outcome of schizophrenia depicted by the sixth-month subtype after an acute episode
  75. Differentiation of Schizophrenia Patients from Healthy Subjects by Mismatch Negativity and Neuropsychological Tests
  76. Poster #238 FACIAL AND PROSODIC EMOTION RECOGNITION DEFICITS PREDICT SPECIFIC DIMENSION OF PSYCHOTIC SYMPTOMS IN SCHIZOPHRENIA
  77. Handedness and schizotypy in non-psychotic relatives of patients with schizophrenia
  78. TIME-FREQUENCY ANALYSIS OF MISMATCH NEGATIVITY IN SCHIZOPHRENIA PATIENTS IN TAIWAN
  79. ANXA7, PPP3CB, DNAJC9, and ZMYND17 Genes at Chromosome 10q22 Associated with the Subgroup of Schizophrenia with Deficits in Attention and Executive Function
  80. MicroRNA Expression Aberration as Potential Peripheral Blood Biomarkers for Schizophrenia
  81. Visuospatial working memory deficits in remitted patients with bipolar disorder: susceptibility to the effects of GABAergic agonists
  82. Performance on the Wisconsin Card Sorting Test in Families of Schizophrenia Patients With Different Familial Loadings
  83. Follow-up of subjects with suspected pre-psychotic state in Taiwan
  84. Thought/Perception Diagnostic Interview Schedule
  85. Acoustic Neuroma Identified After Electroconvulsive Therapy in a Patient With Recurrent Major Depression and Undifferentiated Somatoform Disorder
  86. One‐year post‐hospital medical costs and relapse rates of bipolar disorder patients in Taiwan: a population‐based study
  87. More evidence to support the role of S2 in P50 studies
  88. A case of schizophrenia with dysphagia successfully treated by a multidimensional approach
  89. Corrigendum
  90. Genetic variants of IL-6 and its receptor are not associated with schizophrenia in Taiwan
  91. Bupropion-Related Parkinsonism and Dystonia
  92. Clustering by neurocognition for fine mapping of the schizophrenia susceptibility loci on chromosome 6p
  93. Clinical alertness to valproic acid-induced hyperammonemia-two case reports
  94. Genetic variants in COMT and neurocognitive impairment in families of patients with schizophrenia
  95. The multidimensionality of schizotypy in nonpsychotic relatives of patients with schizophrenia and its applications in ordered subsets linkage analysis of schizophrenia
  96. RASD2, MYH9, and CACNG2 Genes at Chromosome 22q12 Associated with the Subgroup of Schizophrenia with Non-Deficit in Sustained Attention and Executive Function
  97. Successful re-exposure to clozapine following uneventful rechallenge with olanzapine in a patient with neutropenia related to both agents
  98. Impaired Flush Response to Niacin Skin Patch Among Schizophrenia Patients and Their Nonpsychotic Relatives: The Effect of Genetic Loading
  99. HTF9C gene of 22q11.21 region associates with schizophrenia having deficit-sustained attention
  100. Dissociative State and Competence
  101. No association evidence between schizophrenia and dystrobrevin-binding protein 1 (DTNBP1) in Taiwanese families
  102. More evidence supports the association of PPP3CC with schizophrenia
  103. Familial Aggregation in Skin Flush Response to Niacin Patch Among Schizophrenic Patients and Their Nonpsychotic Relatives
  104. Gamma Band Oscillations Reveal Neural Network Cortical Coherence Dysfunction in Schizophrenia Patients
  105. Startle Gating Deficits in a Large Cohort of Patients With Schizophrenia
  106. No association of G72 and d-amino acid oxidase genes with schizophrenia
  107. More severe sustained attention deficits in nonpsychotic siblings of multiplex schizophrenia families than in those of simplex ones
  108. Re-examining sustained attention deficits as vulnerability indicators for schizophrenia: Stability in the long term course
  109. Association evidence of schizophrenia with distal genomic region of NOTCH4 in Taiwanese families
  110. A Single Nucleotide Polymorphism Fine Mapping Study of Chromosome 1q42.1 Reveals the Vulnerability Genes for Schizophrenia, GNPAT and DISC1: Association with Impairment of Sustained Attention
  111. Evaluation ofRGS4 as a candidate gene for schizophrenia
  112. Effects of Background and Prepulse Characteristics on Prepulse Inhibition and Facilitation: Implications for Neuropsychiatric Research
  113. Absence of significant associations between four AKT1 SNP markers and schizophrenia in the Taiwanese population
  114. Patterns and Clinical Correlates of Neuropsychologic Deficits in Patients with Schizophrenia
  115. Dual-modality impairment of implicit learning of letter-strings versus color-patterns in patients with schizophrenia
  116. Memory impairment and auditory evoked potential gating deficit in schizophrenia
  117. Neuropsychological evaluation on three subtypes of schizophrenia
  118. Impairment of color-pattern implicit learning and P50 AEP gating in schizophrenic patients: A 3D brain mapping study